Skip to main content
Premium Trial:

Request an Annual Quote

siRNA "Cure" for Ebola?

In a paper published in The Lancet this week, researchers at the Boston University School of Medicine and their colleagues report their proof-of-concept study, in which they used RNA interference methods to treat Zaire Ebola virus infection in non-human primates. "Two — 66 percent — of three rhesus monkeys given four postexposure treatments of the pooled anti-ZEBOV siRNAs were protected from lethal ZEBOV infection, whereas all macaques given seven post-exposure treatments were protected," the authors write of their siRNA treatment. "This is a breakthrough not only because it may give us a cure for an uncurable, incredibly nasty virus, but also because the same method might work for other viruses, and because we have woefully few effective antiviral treatments," Steven Salzberg writes at the Genomics, Evolution, and Pseudoscience blog (also posted at Forbes' The Science Business blog). Iddo Friedberg at Byte Size Bio maintains a pragmatic view of the study's results. "I seriously doubt we will see controlled human trials before the next natural outbreak, so this is as close as we can get to a proven treatment for Ebola," he writes.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.